
Quest Diagnostics Incorporated (NYSE:DGX – Free Report) – Zacks Research cut their Q1 2027 earnings per share estimates for Quest Diagnostics in a report issued on Thursday, November 12th. Zacks Research analyst Team now anticipates that the medical research company will earn $2.61 per share for the quarter, down from their previous forecast of $2.72. The consensus estimate for Quest Diagnostics’ current full-year earnings is $11.29 per share. Zacks Research also issued estimates for Quest Diagnostics’ Q3 2027 earnings at $3.08 EPS, FY2027 earnings at $11.69 EPS, Q1 2028 earnings at $2.97 EPS, Q2 2028 earnings at $3.24 EPS and FY2028 earnings at $12.77 EPS.
A number of other research firms have also weighed in on DGX. JPMorgan Chase & Co. lifted their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Weiss Ratings upgraded Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a research report on Wednesday, October 21st. Barclays increased their price target on shares of Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 28th. Finally, Argus set a $260.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $248.70.
Quest Diagnostics Stock Performance
Shares of DGX opened at $259.46 on Monday. The stock’s 50-day simple moving average is $241.23 and its 200 day simple moving average is $215.58. The stock has a market capitalization of $28.55 billion, a price-to-earnings ratio of 25.84, a price-to-earnings-growth ratio of 2.32 and a beta of 0.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.58 and a current ratio of 1.70. Quest Diagnostics has a 52-week low of $171.18 and a 52-week high of $262.00.
Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The firm had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the company earned $2.60 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis.
Quest Diagnostics Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 27th. Stockholders of record on Tuesday, January 12th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 annualized dividend and a dividend yield of 1.3%. Quest Diagnostics’s dividend payout ratio is presently 34.26%.
Insider Buying and Selling
In related news, CEO J. Davis sold 10,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total value of $2,427,200.00. Following the sale, the chief executive officer owned 122,423 shares in the company, valued at approximately $29,714,510.56. This trade represents a 7.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Catherine Doherty sold 22,105 shares of Quest Diagnostics stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $248.02, for a total value of $5,482,482.10. Following the sale, the executive vice president directly owned 71,949 shares of the company’s stock, valued at $17,844,790.98. This represents a 23.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,702 shares of company stock valued at $16,730,269 in the last ninety days. 0.88% of the stock is owned by insiders.
Institutional Trading of Quest Diagnostics
Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Quest Diagnostics in the 2nd quarter worth about $1,965,923,000. EdgePoint Investment Group Inc. increased its position in shares of Quest Diagnostics by 35.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 2,243,869 shares of the medical research company’s stock valued at $439,753,000 after purchasing an additional 582,797 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Quest Diagnostics by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,949,535 shares of the medical research company’s stock valued at $382,085,000 after buying an additional 17,987 shares in the last quarter. Bank of America Corp DE purchased a new position in shares of Quest Diagnostics during the 2nd quarter valued at about $410,151,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Quest Diagnostics by 11.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 942,407 shares of the medical research company’s stock worth $199,743,000 after buying an additional 95,804 shares during the last quarter. Hedge funds and other institutional investors own 88.06% of the company’s stock.
Top Quest Diagnostics Stories
Here are a few of the latest stories about DGX:
- Positive Sentiment: A Yahoo Finance article says DGX could be 31% undervalued following a push for the RESULTS Act, providing a potentially supportive policy and valuation angle. Quest Diagnostics stock could be undervalued following RESULTS Act push
- Positive Sentiment: Quest announced a quarterly dividend of $0.86 per share, equivalent to $3.44 annually and a stated yield of about 1.3%. The announcement coincided with DGX reaching a new one-year high. Quest Diagnostics hits a one-year high following dividend announcement
- Neutral Sentiment: SVP Patrick Plewman sold 11,717 shares for about $3.02 million, reducing his holdings by 44.38%. The sale was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive signal about his view of the company. Quest Diagnostics insider share sale
About Quest Diagnostics
Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.
Featured Articles
- Five stocks we like better than Quest Diagnostics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
